secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001140361-23-024502
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire reports Q1 2023 cash $39M; Nyxol PDUFA Sept 28; net loss $5.8M
-----------------------------------------------------------------------

- Cash and cash equivalents of $39.0M, no debt; operations funded into 2025.
- Revenue $1.7M from Nyxol license reimbursement (vs $0 prior year); net loss $5.8M ($0.28/sh) vs $6.6M ($0.35).
- PDUFA date for Nyxol in RM set for Sept 28, 2023; approval triggers $10M milestone payment.
- End-of-Phase 2 meeting with FDA for APX3330 in DR expected in 2H 2023.
- Topline results for Nyxol in presbyopia (VEGA-2) expected in late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123024502/0001140361-23-024502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123024502/brhc20052778_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-024502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer